Shifted helical computed tomography to optimize cardiac positron emission tomography-computed tomography coregistration: Quantitative improvement and limitations

Molecular Imaging

Volumn 9, Issue 5, 2010, Pages 256-267

  Johnson, Nils P ^a,b,c   Pan, Tinsu ^a,b,c   Gould Lance, K ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTENUATION CORRECTION; COMPUTED TOMOGRAPHY; COREGISTRATION; CT DATA; END POINTS; HELICAL COMPUTED TOMOGRAPHIES; HELICAL CT; MISREGISTRATION; PERFUSION ABNORMALITIES; QUANTITATIVE ACCURACY; QUANTITATIVE CRITERIA; Z-DIRECTIONS;

OPTIMIZATION; POSITRON EMISSION TOMOGRAPHY; POSITRONS;

COMPUTERIZED TOMOGRAPHY;

ARTICLE; COMPUTER PROGRAM; HUMAN; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

HUMANS; POSITRON-EMISSION TOMOGRAPHY; SOFTWARE; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 77958088626     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00015     Document Type: Article

References (23)

1. Gould KL. Positron emission tomography in coronary artery disease. Curr Opin Cardiol 2007;22:422-8.
2. Hesse B, Tägil K, Cuocolo A, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:855-97.
3. Strauss HW, Miller DD, Wittry MD, et al. Society of Nuclear Medicine procedure guideline for myocardial perfusion imaging. 2002. Available at: http://interactive.snm.org/docs/pg-ch02-0403.pdf (accessed Aug. 29, 2009).
4. Machac J, Bacharach SL, Bateman TM, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 2006;13: e121-51.
5. Goerres GW, Burger C, Kamel E, et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 2003;226:906-10.
6. Pan T, Mawlawi O, Luo D, et al. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 2006;33:3931-8.
7. Le Meunier L, Maass-Moreno R, Carrasquillo JA, et al. PET/CT imaging: effect of respiratory motion on apparent myocardial uptake. J Nucl Cardiol 2006;13:821-30.
8. Martinez-Möller A, Souvatzoglou M, Navab N, et al. Artifacts from misaligned CT in cardiac perfusion PET/CT studies: frequency, effects, and potential solutions. J Nucl Med 2007;48:188-93.
9. Alessio AM, Kohlmyer S, Branch K, et al. Cine CT for attenuation correction in cardiac PET/CT. J Nucl Med 2007;48:794-801.
10. Gould KL, Pan T, Loghin C, et al. Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: a definitive analysis of causes, consequences, and corrections. J Nucl Med 2007;48:1112-21.
11. Nye JA, Esteves F, Votaw JR. Minimizing artifacts resulting from respiratory and cardiac motion by optimization of the transmission scan in cardiac PET/CT. Med Phys 2007;34:1901-6.
12. Souvatzoglou M, Bengel F, Busch R, et al. Attenuation correction in cardiac PET/CT with three different CT protocols: a comparison with conventional PET. Eur J Nucl Med Mol Imaging 2007;34:1991-2000.
13. Lautamäki R, Brown TL, Merrill J, Bengel FM. CT-based attenuation correction in (82) Rb-myocardial perfusion PET-CT: incidence of misalignment and effect on regional tracer distribution. Eur J Nucl Med Mol Imaging 2008;35:305-10.
14. McQuaid SJ, Hutton BF. Sources of attenuation-correction artefacts in cardiac PET/CT and SPECT/CT. Eur J Nucl Med Mol Imaging 2008;35:1117-23.
15. Loghin C, Sdringola S, Gould KL. Common artifacts in PET myocardial perfusion images due to attenuation-emission misregistration: clinical significance, causes, and solutions. J Nucl Med 2004;45:1029-39.
16. Gould KL, Pan T, Loghin C, et al. Reducing radiation dose in reststress cardiac PET/CT by single post stress cine CT for attenuation correction: quantitative validation. J Nucl Med 2008;49:738-45.
17. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 2003;41:263-72.
18. Johnson NP, Gould KL. Clinical evaluation of a new concept: resting myocardial perfusion heterogeneity quantified by markovian analysis of PET identifies coronary microvascular dysfunction and early atherosclerosis in 1, 034 subjects. J Nucl Med 2005;46:1427-37.
19. Sdringola S, Loghin C, Boccalandro F, Gould KL. Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up. J Nucl Med 2006;47:59-67.
20. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274:894-901.
21. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
22. Gould KL. Assessing progression or regression of CAD: the role of perfusion imaging. J Nucl Cardiol 2005;12:625-38.
23. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701-12.